Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs)
Theranostics · 2024 · 14 (1) · 133-142
DOI: 10.7150/thno.88619 ↗Kurz gefasst
Fachartikel in der Zeitschrift Theranostics, 2024. Verfasst von Richard P Baum und 6 weiteren Autor:innen. Beteiligte Einrichtung: CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany. Hauptthemen laut MEDLINE: Neoplasms, Unknown Primary, Neuroendocrine Tumors, Organometallic Compounds. Die Arbeit wurde bisher 11-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National University of Singapore, NUS Theranostics Center of Excellence, NUS School of Medicine Nanomedicine Translational Research Programme.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, Wiesbaden, Germany.
- Theranostics Center for Molecular Radiotherapy and Precision Oncology, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, Germany.
- Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Department of Nuclear Medicine, Peking Union Medical College Hospital. Chinese Academy of Medical Science and Peking Union Medical College, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear M…
- Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Förderung
- National University of Singapore
- NUS Theranostics Center of Excellence
- NUS School of Medicine Nanomedicine Translational Research Programme
- National Medical Research Counci
- NMRC Centre Grant Programme
Zitieren
APA
Baum, R. P., Wang, P., Jakobsson, V., Zhao, T., Schuchardt, C., Khong, P. L., & Zhang, J. (2024). Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs). Theranostics, 14(1), 133-142. https://doi.org/10.7150/thno.88619
Vancouver
Baum RP, Wang P, Jakobsson V, Zhao T, Schuchardt C, Khong PL, et al. Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs). Theranostics. 2024;14(1):133-142. doi:10.7150/thno.88619
BibTeX
@article{Baum2024,
author = {Baum, Richard P and Wang, Peipei and Jakobsson, Vivianne and Zhao, Tianzhi and Schuchardt, Christiane and Khong, Pek-Lan and Zhang, Jingjing},
title = {Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs)},
journal = {Theranostics},
year = {2024},
volume = {14},
number = {1},
pages = {133--142},
doi = {10.7150/thno.88619}
}
EUVIMED